

May 15, 2026**The National Stock Exchange of India Limited,**Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai – 400051.

Symbol: REDINGTON

BSE LimitedFloor 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai — 400 001

Scrip: 532805

Sir/Madam,**Sub: Newspaper advertisement pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed copies of the newspaper publication of the Financial Results for the quarter and year ended March 31, 2026, as published in Business Standard (English) and Makkal Kural (Tamil).

The above information will also be hosted on the Company's website at <https://redingtongroup.com/>

This is for your information and records.

Thank you

For Redington Limited**K Vijayshyam Acharya
Company Secretary**

38

हजार प्रयास
हो सकेगा आवास



राष्ट्रीय
आवास बैंक
NATIONAL
HOUSING BANK

Statutory Body under The Government of India
Core-5A, 3rd - 5th Floor, India Habitat Centre,
Lodhi Road, New Delhi - 110003

Particulars	Financial Results for the Period Ended March 31, 2026 (₹ in lakhs)					
	Quarter Ended	Quarter Ended	Quarter Ended	9M Ended	9M Ended	FY Ended
	31.03.2026	31.03.2025	31.12.2025	31.03.2026	31.03.2025	30.06.2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Total Income from operations*	1,88,312	1,96,600	1,86,667	5,72,286	5,66,945	7,69,221
2. Net Profit/(Loss) for the period (before tax, Exceptional and /or Extraordinary items*)	50,362	69,519	55,444	1,70,804	1,92,632	2,54,844
3. Net Profit/(Loss) for the period before tax, (after Exceptional and / or Extraordinary items*)	50,362	69,519	55,444	1,70,804	1,92,632	2,54,844
4. Net Profit/(Loss) for the period after tax(after Exceptional and /or Extraordinary items*)	33,562	50,552	41,334	1,23,874	1,42,229	1,90,941
5. Total Comprehensive income for the period[comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income(after Tax)]	NA	NA	NA	NA	NA	NA
6. Equity Share Capital	1,45,000	1,45,000	1,45,000	1,45,000	1,45,000	1,45,000
7. Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year. ⁵	15,11,587	13,20,077	15,11,587	15,11,587	13,20,077	15,11,587
8. Earning Per Share (EPS)	NA	NA	NA	NA	NA	NA
(a) Basic	NA	NA	NA	NA	NA	NA
(b) Diluted	NA	NA	NA	NA	NA	NA

*Income from operations includes Interest Income on Advances, Bank Deposits and Investments.

*Exceptional and /or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with IndAS Rules/AS Rules, whichever is applicable.

*For the quarter/Nine Months ended taken as per audited balance sheet of last financial year

Notes :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 14, 2026 at New Delhi.
- The above is an extract of the detailed format of quarterly /yearly financial results filed with the Stock Exchange(s) under regulation 52 of the SEBI (LODR) Regulations, 2015. The full format of the quarterly/yearly financial results is available on the websites of the BSE and NSE (www.bseindia.com/www.nseindia.com) and the Bank's Website (www.nhb.org.in).
- For the other line items referred in regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the BSE and NSE and can be accessed on the URL (www.nseindia.com and www.bseindia.com).
- The impact on net profit/loss, total comprehensive income or any other relevant financial items(s) due to change(s) in accounting policies shall be disclosed by means of a footnote. NIL



For and on behalf of the Board of Directors
Sanjay Shukla
Managing Director

Place: New Delhi
Date: May 14, 2026

REDINGTON LIMITED

Registered office: Block 3, Plathin, Redington Tower, Inner Ring Road, Saraswathy Nagar West,
4th Street, Puzhuthivakkam, Chennai - 600 091
Website: www.redingtongroup.com | Email: investors@redingtongroup.com
CIN: L52599TN1961PLC028758
Board No: +91-44-42243111

Redington
SEAMLESS PARTNERSHIPS

Extract of Consolidated Financial Results for the Quarter and Year Ended March 31, 2026

Sl. No.	Particulars	Consolidated			
		Quarter Ended	Quarter Ended	Year Ended	Year Ended
		March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
			(Audited)	(Audited)	
1.	Revenue from operations	33,213.03	26,439.68	1,19,162.36	99,333.65
2.	Profit before exceptional item and tax	547.53	522.37	1,849.40	1,709.04
3.	Profit before tax	395.22	1,148.14	1,697.09	2,334.81
4.	Profit after exceptional item and tax	287.58	917.74	1,284.15	1,820.62
5.	Total comprehensive income	573.07	861.61	1,758.39	1,819.94
6.	Equity share capital	156.35	156.35	156.35	156.35
7.	Reserves and surplus (Other equity except Securities premium account)	9,828.26	8,388.57	9,828.26	8,388.57
8.	Securities premium account	176.12	176.12	176.12	176.12
9.	Networth	10,160.73	8,721.04	10,160.73	8,721.04
10.	Non-controlling interest	263.25	476.16	263.25	476.16
11.	Outstanding Debt	2,637.45	2,619.18	2,637.45	2,619.18
12.	Debt-equity ratio	0.25	0.28	0.25	0.28
13.	Earnings per Equity Share: (Face Value - ₹ 2/- per share) (not annualized for quarters)				
	1. Basic (in ₹)	5.01	8.51	19.06	20.53
	2. Diluted (in ₹)	5.01	8.51	19.06	20.53
14.	Debt service coverage ratio (in times) (not annualised)	7.06	7.41	5.90	5.66
15.	Interest service coverage ratio (in times) (not annualised)	8.60	7.41	6.16	6.18

Notes

1. Summarized Standalone Financial Results of the Company is as under:

Sl. No.	Particulars	Standalone			
		Quarter Ended	Quarter Ended	Year Ended	Year Ended
		March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
			(Audited)	(Audited)	
1.	Revenue from operations	34,772.56	13,121.36	63,801.19	48,902.50
2.	Profit before tax	997.03	276.08	1,571.06	1,698.21
3.	Profit after tax	820.33	209.45	1,243.90	1,443.76

- The above is an extract of the detailed format of Quarterly / Half-Yearly / Annual Financial Results filed with the Stock Exchanges under Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available in the website of the National Stock Exchange of India Limited (NSE) www.nseindia.com and BSE Limited (BSE) www.bseindia.com and are available in the Company's website www.redingtongroup.com.
- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of Redington Limited at their meeting held on May 13, 2026.



(Scan for full results)

Place : Chennai
Date : May 13, 2026

https://redingtongroup.com/wp-content/uploads/2026/05/Q4-Financials.pdf

For Redington Limited

S V Krishnan
Finance Director (Whole-time)

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



Q-LINE BIOTECH LIMITED

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE")

Our Company was originally incorporated as "POCT Services Private Limited" on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited", and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of incorporation, change of registered office of our Company, please refer to chapter titled "History and Corporate Structure" beginning on page 149 of the Draft Red Herring Prospectus dated September 30, 2025 filed with the NSE Emerge.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012

Contact Person: Akhand Pratap Singh, Company Secretary & Compliance Officer,

Tel No: +91 522-2435570 ; E-mail: compliance@qlinebiotech.com ; Website: www.qlinebiotech.com ; Corporate Identity Number: U74120UP2010PLC042528.

NOTICE TO INVESTORS ("NOTICE")

INITIAL PUBLIC OFFER OF UPTO 70,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF Q-LINE BIOTECH LIMITED ("OUR COMPANY" OR "QLBL" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ 100/- PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ 7,05,32,00,000/- ("PUBLIC ISSUE").

*Our Company, in consultation with the Book Running Lead Managers, has undertaken a Pre-IPO Placement of 8,00,000 Equity Shares at an issue price of ₹ 343 per Equity Shares (including a premium of ₹ 333 per Equity Shares) for a cash consideration aggregating to ₹ 27,44,00,000/-, on May 13, 2026. The size of the Fresh Issue has been reduced by 8,00,000 number of equity shares and accordingly, the size of the Fresh Issue is up to 62,53,200 equity shares.

Potential bidders may note the following:

Our Company, in consultation with the BRLMs, has undertaken the Pre-IPO Placement of 8,00,000 Equity Shares at an issue price of ₹ 343 per Equity Share (including a premium of ₹ 333 per Equity Share) for an amount aggregating to ₹ 27,44,00,000/-, by way of a private placement in accordance with Section 42, 62 of the Companies Act, 2013 read with the Companies (Prospectus and Allotment of Securities) Rules, 2014 and the Companies (Share Capital and Debentures) Rules, 2014, each as amended.

The Pre-IPO Placement has been undertaken pursuant to the approval of the Board and Shareholders in their meetings, held on May 11, 2026 and May 12, 2026 respectively.

The Company has allotted Equity Shares in the Pre-IPO Placement pursuant to the resolution passed by the Board in its meeting held on May 13, 2026, in the manner as set forth below:

Date of allotment	Number of Equity Shares allotted	Issue price per Equity Share (in INR)	Total consideration paid (in INR)	Name of the Allottee
May 13, 2026	4,35,502	343	14,93,77,186	Vikas Vijaykumar Khemani
May 13, 2026	2,33,300	343	8,00,21,900	Calliope Capital Advisors LLP
May 13, 2026	29,155	343	1,00,00,165	Sahastra Advisors Private Limited
May 13, 2026	29,155	343	1,00,00,165	SB Opportunities Fund II
May 13, 2026	29,155	343	1,00,00,165	Deepak Malik
May 13, 2026	29,155	343	1,00,00,165	Nisha Jain And Priyanka Havelia
May 13, 2026	7,289	343	25,00,127	Kunal Niranjan Shah
May 13, 2026	7,289	343	25,00,127	Rajkumar Mangilal Borana

Accordingly, pursuant to the Pre-IPO Placement, the size of the Fresh Issue has now been reduced by such number of Equity Shares aggregating up to 8,00,000 equity shares. The abovementioned allottee is not, in any manner, connected with the Company, the Promoters, members of the Promoter Group, the Directors, the Key Managerial Personnel, the group Companies and their respective directors and key managerial personnel.

Please note that the Equity Share allotted pursuant to the above Pre-IPO placement, shall be subject to Lock-in, in accordance with terms of Regulation 239 of the SEBI (ICDR) Regulations, 2018.

Please further note that the Notice does not reflect all the changes that have occurred between the date of filing of the DRHP and the date hereof, and accordingly does not include all the changes and/or updates that will be included in the Red Herring Prospectus and the Prospectus. The above notice is to be read in conjunction with the DRHP. Further, the company will suitably update the relevant section in the Red Herring Prospectus and Prospectus to be filed with ROC and the Stock Exchange, to reflect the factual position pursuant to the allotment as on the date of the Red Herring Prospectus and Prospectus.

BOOK RUNNING LEAD MANAGERS TO THE ISSUE

Hem Securities

HEM SECURITIES LIMITED
Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, Maharashtra, India.
Tel. No.: +91-22-4906 0000 ; Email: ib@hemsecurities.com
Investor Grievance Email: redressal@hemsecurities.com
Website: www.hemsecurities.com
Contact Person: Sourabh Garg
SEBI Registration Number: INM000010981
CIN: U67120RJ1995PLC010390

Share India
You generate, we multiply

SHARE INDIA CAPITAL SERVICES PRIVATE LIMITED
Address: A 25, Basement, Sector 64, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301
Tel No.: +91 0120-6483000
Email: mb@shareindia.com
Website: www.shareindia.com
Contact Person: Kunal Bansal
SEBI Reg. No.: INM000012537

Purva Sharegistry

PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED
Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011
Tel. No.: 91 22 2301 2517 / 8261
Fax No.: +91-022-23012517
Email: support@purvashare.com
Website: www.purvashare.com
Contact Person: Deepali Dhuri
SEBI Registration No.: INR000001112

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For Q-Line Biotech Limited
On behalf of the Board of Directors
Sd/-
Akhand Pratap Singh
Company Secretary and Compliance Officer

Q-Line Biotech Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the DRHP dated September 30, 2025 with NSE Emerge. The DRHP is available on the website of NSE Emerge at www.nseindia.com, website of the Company at www.qlinebiotech.com and the websites of the BRLMs at https://www.hemsecurities.com and www.shareindia.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled "Risk Factors" of the RHP once available. Potential investors should not rely on the DRHP filed with NSE for making any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of securities for sale in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. However, no offering of securities is being made in the United States.

Manaksia Coated Metals And Industries Limited

Corporate Identity Number: L27100WB2010PLC144409
Registered Office: Bikaner Building, 8/1, Lal Bazar Street, 3rd Floor, Kolkata, West Bengal - 700 001
E-mail: info@mcml.in, Website: www.manaksia.coatedmetals.com
Phone: +91-33-2243 5053/5054

SPECIAL WINDOW FOR RE-LODGE MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES

Notice is hereby given that the Securities and Exchange Board of India vide its Circular No. HO/38/13/11(2)2026-MIRSD-POD/13750/2026 dated January 30, 2026 ("Circular") has facilitated mechanism for a "Special Window for Transfer and Dematerialisation of Physical Securities" and accordingly all physical shares which were sold/purchased prior to April 1, 2019 including those which were lodged earlier for transfer with the Company or its Registrar and Transfer Agent (RTA) prior to discontinuation of physical mode of transfer, i.e., April 01, 2019 and rejected/returned by the Company/RTA due to deficiency in the documents and was required to be re-lodged with requisite documents on or before the cut-off date fixed for re-lodgement of such transfer deeds, i.e., March 31, 2021 shall be provided with an opportunity to lodge/re-lodge the same with the Company/RTA during a special window period of one year from February 05, 2026 till February 4, 2027. However, in all the cases, the claimants must have the original security certificate with them and the said shares should not have been transferred to the Investor Education and Protection Fund Authority for any reasons. Further, the securities once transferred shall be mandatorily credited to the transferee only in demat mode and shall be under lock-in for a period of one year from the date of registration of transfer and such securities shall not be transferred / lien -marked / pledged during the said lock-in period. For further details you may contact the Company Secretary of the Company or the Registrar and Transfer Agent of the Company, i.e., Maheshwari Datalytics Private Limited, 23, RN Mukherjee Road, 5th floor, Kolkata-700001 (WB), Tel No. (033-2248 2248) E-mail: info@manaksia.coatedmetals.com.

A copy of the Circular is also available on the website of the Company at www.manaksia.coatedmetals.com.

For Manaksia Coated Metals & Industries Limited
Sd/-

Shruti Agarwal
Company Secretary & Compliance Officer
M. No. - F12124
Place: Kolkata
Date: 15.05.2026

RESONANCE SPECIALTIES LIMITED

(CIN No. L25209MH1989PLC051993)

REGD. OFFICE : 54-D, Kandivali Industrial Estate, Charkop, Kandivali (West) MUMBAI 400067

Website: www.resonancesl.com TEL: 022 6857 2827. GST No-27AAAC9590Q12W. Email: info@resonancesl.com

FINANCIAL RESULTS FOR THE QUARTER ENDED AND YEAR ENDED 31ST MARCH, 2026 (Rs. in Lakhs)

Sr. No.	Particulars	Quarter Ended		Year Ended	Year Ended
		31st March, 2026 Audited	31st March, 2025 Un-Audited	31st March, 2026 Audited	31st March, 2025 Audited
1	Total Income from operations	2,447.71	2,296.27	2,420.17	9,024.75
2	Net Profit / (Loss) for the period (Before Tax, Exceptional and /or Extra ordinary items)	599.16	338.36	419.54	1,407.35
3	Net Profit / (Loss) for the period (before Tax, after Exceptional and /or Extra ordinary items)	599.16	338.36	417.78	1,407.35
4	Net Profit / (Loss) for the period (after Tax, after Exceptional and /or Extra ordinary items)	459.56	251.28	305.75	1,039.58
5	Comprehensive income for the period (Comprising profit & loss) for the period (after tax) and other comprehensive income (after tax)	462.76	248.80	303.99	1,037.04
6	Equity Share Capital	1,154.40	1,154.40	1,154.40	1,154.40
7	Reserves (Excluding Revaluation reserve as shown in the Audited Balance sheet of the previous year				5,802.75
8	Earning per Share (of Rs 10/-each) (for continuing and discontinued operations)- (basic & Diluted)	3.98	2.18	2.63	9.01

Notes :

- The financial results of the Company have been prepared in accordance with the Companies (Indian Accounting Standard) Rules' 2015 (IND-AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The above results have been reviewed by the audit committee and thereafter approved by the Board of Directors in their meeting held on 14th May 2026.
- The Board has recommended a dividend of Rs. 1/- per share (10%) for the financial year 2025-26
- In accordance with Ind AS-108 "Operating Segments", the company has only one reportable primary business segment i.e. "Chemical Manufacturing". However, the company has secondary geographical segment which is disclosed in the financial statement as per Ind AS- 108. Information about secondary geographical segments as per financial statements

Particulars	(Rs. In Lakhs)	
	April to March 26	April to March 25
Segment Revenue		
- India	3,669.69	4,369.58
- Outside India	5,355.06	3,411.08
Total	9,024.75	7,780.66

The segment asset and segment capital expenditure attributable to the segment "Outside India" is less than 10% of the respective total assets and total capital expenditure and therefore not disclosed separately.

- The Company post notification of new labour code has evaluated its implication on employee benefits and considered the same while making provision for employee benefits including actuarial based gratuity and leave encashment provisions in the financial results. On account of the change the incremental impact is Rs.10.40 lakhs which is charged to the Profit and Loss Statement.
- As at 31st March, 2026 the company does not have any subsidiary/associate/Joint venture entity (IE).
- *The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended March 31, and unaudited year-to-date figures up to the third quarter ended December 31, which were subjected to limited review
- The figures for the previous financial period have been regrouped/rearranged wherever necessary.

By the order of the Board
For RESONANCE SPECIALTIES LIMITED

Sd/-

Charchit Jain

Whole Time Director

DIN: 09344495

Place: Mumbai
Dated : 14th May 2026